CX3CR1 and neoplasm: By reducing these activities, the CX3CR1 monoclonal antibody can disrupt recruitment, facilitate remodeling, and alter the MDSC compartment in the tumor microenvironment (Supplementary Figure 6), making the combination of CX3CR1 and PD-1 antibody blockade a promising combination therapeutic strategy.